ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Emerging targets for radioprotection and radiosensitization in radiotherapy.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- PKCδ Regulates DNA Damage and Cell Death through a SIRT6/Nrf2-dependent Antioxidant Response.Molecular cancer research : MCR · 2025Article
- DNA repair and the contribution to chemotherapy resistance.Genome medicine · 2025Review
- Combination ofScientific reports · 2021Article
- Iron oxide nanoparticle-induced hematopoietic and immunological response in rats.RSC advances · 2020Article
- DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.Signal transduction and targeted therapy · 2020Review
- Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2.EJNMMI research · 2020Article
- Dislocation Engineered PtPdMo Alloy With Enhanced Antioxidant Activity for Intestinal Injury.Frontiers in chemistry · 2019Article
- The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells.Frontiers in oncology · 2019Article
- Profiles of Radioresistance Mechanisms in Prostate Cancer.Critical reviews in oncogenesis · 2018Review
- Development and Characterization of VEGF165-Chitosan Nanoparticles for the Treatment of Radiation-Induced Skin Injury in Rats.Marine drugs · 2016Article
- Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is the biggest force acting behind cancer treatment, yet the vast majority of patients get only modest benefit. The successive failure of targeted therapies in radiotherapy lies in the non-discriminative killing of both normal and cancer cells. However, there is still a reason for optimism due to recent advancement made in cancer biology which unrevealed many new deregulated pathways in cancer and their response towards drug and radiation. In this review, we comprehensively discussed novel and promising druggable target which can be exploited for tumor radiosensitization in addition to normal tissue radioprotection in radiotherapy, for better tumor controllability and patient quality of life. In the last part, we also discussed the radiation countermeasure agents in brief.
Indexed as
Identifiers
27318945What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.